BioLineRx to Present New GLIX1 Preclinical Data at ASCO 2026, Highlighting PARP Inhibitor Synergy

summarizeSummary

BioLineRx announced that new preclinical data for its lead asset GLIX1, including synergistic activity with PARP inhibitors, will be presented at the ASCO 2026 Annual Meeting, reinforcing its potential in glioblastoma and other cancers.

check_boxKey Events

• ASCO 2026 Presentation

  BioLineRx and Hemispherian AS will present two abstracts featuring GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting from May 29-June 2.

• New Preclinical Data

  The abstracts detail GLIX1's novel mechanism of action as a TET2 activator, showing high potency and strong antitumor activity in glioblastoma xenograft models, with efficient brain penetration.

• PARP Inhibitor Synergy

  Preclinical studies demonstrated synergistic antitumor activity when GLIX1 was combined with PARP inhibitors across a wide range of cancer cell lines, suggesting enhanced efficacy in various cancers.

• Clinical Trial Progress

  The first-in-human Phase 1/2a clinical trial for GLIX1 in glioblastoma, initiated in March, is actively enrolling patients, with updates expected in H2 2026.

auto_awesomeAnalysis

This filing provides significant positive updates on BioLineRx's lead oncology asset, GLIX1, by announcing new preclinical data to be presented at the prestigious ASCO conference. The data highlights GLIX1's novel mechanism of action and, critically, its synergistic potential with PARP inhibitors, which could broaden its applicability and market opportunity beyond glioblastoma. For a company that recently disclosed a "going concern" warning, demonstrating strong progress and potential for its key pipeline asset is crucial for investor confidence and future financing.